Status:
UNKNOWN
Plaque Stability and Metabolomics in Coronary Heart Disease
Lead Sponsor:
Shaanxi Provincial People's Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-90 years
Brief Summary
At present, the investigators don't know the relationship between plaque stability and the metabonomics changes. In the present study, investigators will evaluate the plaque stability by intravascular...
Eligibility Criteria
Inclusion
- Patients who diagnosed with stable coronary heart disease and evaluated for plaque stability by IVUS will be recruited.
Exclusion
- renal insufficiency with serum creatinine \> 20 mg/L;
- regnant/lactating women, or the women receive hormone replacement therapy in premenopausal or postmenopausal;
- patients have a history of abusing alcohol or other drugs in the past two years, active hepatitis, cirrhosis;
- endocrine abnormalities without therapy (diabetic ketoacidosis, thyroid disease, etc.);
- The body's inflammatory disease, rheumatoid arthritis, osteoarthritis, ulcerative bowel disease, systemic lupus erythematosus (sle), etc.), myositis/myopathy, cancer;
- Dilated cardiomyopathy, valvular heart disease, persistent atrial fibrillation;
- patients recently injured;（8）Other researchers don't agree to join this study.
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05270330
Start Date
July 1 2021
End Date
July 31 2024
Last Update
March 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaanxi Provincial People's Hospital
Xi'an, Shaanxi, China, 710061